^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Selective serotonin reuptake inhibitor

    Related drugs:
    22h
    Trazodone and the Risk of Serious Adverse Events (clinicaltrials.gov)
    P=N/A, N=31459, Completed, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
    New trial • Adverse events • Serious adverse event
    3d
    The exploration of the efficacy and possible mechanisms of paroxetine combined with liraglutide in the treatment of depression associated with obesity. (ChiCTR2500113481)
    P=N/A, N=24, Not yet recruiting, Zhongda Hospital Affiliated to Southeast University; Zhongda Hospital Affiliated to Southeast University
    New trial
    3d
    Citalopram treatment window Study Based on PK-PD Model: Correlation analysis of therapeutic drug Monitoring and clinical outcomes in Patients with sleep Disorders and Depression (ChiCTR2500112989)
    P=N/A, N=200, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New trial
    3d
    Effect of rTMS combined with sertraline on Inflammatory levels and Its correlation in adolescent patients with depression (ChiCTR2500112243)
    P=N/A, N=150, Recruiting, The Affiliated Xuzhou Oriental Hospital of Xuzhou Medical University; The Affiliated Xuzhou Oriental Hospital of Xuzhou Medical University
    New trial
    3d
    Clinical study of the ability of celecoxib combined with olanzapine and paroxetine hydrochloride to improve depression,anxiety and analgesic effects in patients after hemorrhoidal surgery (ChiCTR2500112052)
    P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University
    New trial
    |
    celecoxib oral • olanzapine
    3d
    Study on resting state brain magnetic resonance imaging of DBT combined with drug therapy in adolescents with depression (ChiCTR2600116754)
    P=N/A, N=100, Completed, University City Hospital of Chongqing Medical University; University City Hospital of Chongqing Medical University
    New trial
    3d
    Efficacy and Safety of Idebenone Combined With Escitalopram in Post-stroke Depression: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (ChiCTR2500111442)
    P4, N=216, Not yet recruiting, Xuanwu Hospital Capital Medical University; Xuanwu Hospital Capital Medical University
    New P4 trial
    12d
    ESPRIT: sElective Serotonin reuPtake inhibitoRs In posT-covid (clinicaltrials.gov)
    P3, N=160, Not yet recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    New P3 trial
    18d
    Acupuncture as a modulator of microglial polarization and pyroptosis in depression: evidence from a chronic unpredictable mild stress rat model. (PubMed, Metab Brain Dis)
    Acupuncture alleviates depression-like behaviors in CUMS-induced rats by modulating microglial polarization and inhibiting neuroinflammation-mediated pyroptosis. Our findings provide further evidence supporting acupuncture as a viable strategy for depression treatment.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CASP1 (Caspase 1)
    |
    fluoxetine
    18d
    Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy. (PubMed, Mol Ther Oncol)
    Furthermore, repurposing paroxetine, one of the Food and Drug Administration-approved selective serotonin reuptake inhibitors (SSRIs) with GRK-2 inhibitory action, enhanced this effect, leading to greater lymphocyte circulation, activation, and improved survival in an orthotopic syngeneic mouse model. By overcoming key mechanisms of immune suppression and repurposing a widely available, clinically safe drug, this strategy represents a highly translatable approach to enhancing the efficacy of immunovirotherapy for gliomas.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    19d
    Lux4UA: Building Ukraine's Strength in PTSD Treatment and Research (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, University of Luxembourg | Not yet recruiting --> Recruiting
    Enrollment open